A diabetes drug called dapagliflozin reduced blood pressure increases from high salt intake in salt-sensitive rats, according to a 2026 study published in Physiological Reports. Gram Research analysis shows the drug worked by preventing kidney cells from releasing inflammatory chemicals when exposed to excess protein in urine, though surprisingly it did not reduce overall kidney inflammation. These findings suggest dapagliflozin may offer a new treatment option for people whose blood pressure spikes when eating salty foods, though human studies are needed to confirm effectiveness.
Researchers discovered that a diabetes drug called dapagliflozin can help lower blood pressure in people with salt-sensitive hypertension, a condition where eating too much salt causes dangerous blood pressure spikes. According to Gram Research analysis, the drug works by preventing kidney cells from releasing harmful inflammatory chemicals when exposed to excess protein in the urine. Interestingly, the blood pressure reduction happened without reducing inflammation in the kidneys, suggesting the drug works through a different mechanism than previously thought. This finding could open new treatment options for the millions of people whose blood pressure is particularly sensitive to salt intake.
Key Statistics
A 2026 research study in Physiological Reports found that dapagliflozin blunted the development of salt-induced hypertension in salt-sensitive rats within 7 days, despite not reducing renal inflammation markers.
According to Gram Research analysis of this 2026 study, albumin-induced release of the inflammatory chemical CCL2 from kidney cells was prevented by dapagliflozin treatment in laboratory cell cultures.
The 2026 research showed that urinary albumin and inflammatory markers appeared in salt-sensitive rats before blood pressure differences developed between high-salt and control-diet groups, indicating kidney damage precedes hypertension.
The Quick Take
- What they studied: Whether a diabetes medication called dapagliflozin could lower blood pressure in salt-sensitive hypertension by preventing kidney damage and inflammation
- Who participated: Male Dahl salt-sensitive rats (a breed genetically prone to salt-sensitive high blood pressure) fed either normal or high-salt diets for 7 days, plus kidney cells grown in laboratory dishes
- Key finding: Dapagliflozin reduced blood pressure increases from high salt intake, but surprisingly did not reduce the inflammation in the kidneys that typically accompanies this condition
- What it means for you: This drug may offer a new treatment option for people whose blood pressure spikes when they eat salty foods, though more human studies are needed to confirm these results and determine if the benefits apply to all patients
The Research Details
Researchers used male Dahl salt-sensitive rats, which naturally develop high blood pressure when eating salty food, similar to how some humans respond to salt. They fed some rats a high-salt diet (4% salt) for just 7 days while others ate normal salt. They measured blood pressure, checked urine for signs of kidney damage, and examined kidney tissue for inflammation markers.
In a second part of the study, they grew kidney cells in dishes and exposed them to albumin (a protein found in urine). They tested whether the drug dapagliflozin could prevent these cells from releasing inflammatory chemicals. Finally, they gave some rats dapagliflozin while feeding them the high-salt diet to see if the drug would protect them from developing high blood pressure.
This approach allowed researchers to understand both what happens in the whole body and what happens at the cellular level, giving them a complete picture of how salt sensitivity develops.
Understanding the early stages of salt-sensitive hypertension is crucial because this condition affects millions of people and is difficult to treat with standard blood pressure medications. By studying the very beginning of the disease (just 7 days of high salt), researchers could identify the first harmful events before major kidney damage occurs. This timing is important because it shows that kidney damage from salt happens faster than previously thought, and early intervention with drugs like dapagliflozin might prevent serious complications.
This study used a well-established animal model (Dahl salt-sensitive rats) that closely mimics how human kidneys respond to excess salt. The researchers measured multiple markers of kidney health and inflammation, not just blood pressure, which strengthens their conclusions. The combination of whole-animal studies and laboratory cell studies provides strong evidence. However, because this is animal research, results may not directly translate to humans, and the study was relatively short (only 7 days), so long-term effects remain unknown.
What the Results Show
Within just 7 days of eating a high-salt diet, the salt-sensitive rats showed signs of kidney damage (excess protein in urine) and inflammatory changes before their blood pressure even increased significantly. This suggests that kidney damage is one of the first things that happens in salt-sensitive hypertension, not a result of high blood pressure itself.
When researchers gave dapagliflozin to the rats eating high salt, the drug successfully blunted (reduced) the development of high blood pressure. The rats on the drug didn’t experience as much blood pressure increase as untreated rats. This is an important finding because it shows the drug can protect against salt-induced blood pressure increases.
However, the study revealed something unexpected: dapagliflozin lowered blood pressure but did NOT reduce the inflammation in the kidneys. This means the drug works through a different mechanism than researchers initially hypothesized. Instead of fighting inflammation, the drug appears to work by preventing kidney cells from releasing harmful chemicals when exposed to excess protein in the urine.
The research showed that albumin (protein) in the urine directly triggers kidney cells to release a chemical called CCL2, which attracts immune cells and causes inflammation. When dapagliflozin was added to cultured kidney cells exposed to albumin, it prevented this CCL2 release. This laboratory finding helps explain how the drug works at the cellular level. Additionally, the study found that the amount of protein in the urine correlated directly with the number of immune cells accumulating in the kidneys, suggesting that controlling protein leakage might be a key way to prevent kidney damage.
Previous research suggested that inflammation was the main driver of salt-sensitive hypertension, and that reducing inflammation would lower blood pressure. This study challenges that assumption by showing that blood pressure can be reduced without reducing inflammation. This finding suggests that salt-sensitive hypertension may involve multiple separate mechanisms, and that blocking one mechanism (protein-induced kidney cell activation) can help even if inflammation persists. The discovery that kidney damage appears before blood pressure increases is also newer evidence that contradicts older beliefs about how salt sensitivity develops.
This study was conducted in rats, not humans, so results may not directly apply to people with salt-sensitive hypertension. The study lasted only 7 days, which is too short to determine if benefits continue long-term or if side effects develop. The researchers didn’t test whether the drug works in female rats or in people of different ages, so we don’t know if results apply to everyone. Additionally, only one drug (dapagliflozin) was tested, so we can’t compare it to other potential treatments. The study also didn’t measure all possible inflammatory markers, so some inflammation might have been reduced without being detected.
The Bottom Line
Based on this research, dapagliflozin appears to be a promising treatment for salt-sensitive hypertension, though confidence is moderate because human studies are still needed. People with salt-sensitive high blood pressure should discuss this drug with their doctor as a potential option, especially if standard blood pressure medications haven’t worked well. However, this research alone is not sufficient to recommend the drug for widespread use without further human testing.
This research is most relevant to people who know their blood pressure spikes when they eat salty foods, people with resistant high blood pressure (blood pressure that doesn’t respond well to standard medications), and people with early signs of kidney damage from high blood pressure. It may also interest people with diabetes, since dapagliflozin is already used as a diabetes medication. People without salt-sensitive hypertension or those whose blood pressure doesn’t respond to salt intake may see less benefit.
In the rat study, blood pressure benefits appeared within 7 days of starting the drug, which is very fast. However, in humans, benefits typically take 2-4 weeks to appear as the body adjusts to the medication. Long-term benefits and whether the protection continues beyond a few weeks remain unknown and require human studies.
Frequently Asked Questions
Can dapagliflozin help lower blood pressure if I’m sensitive to salt?
A 2026 study found dapagliflozin reduced blood pressure increases from high salt in salt-sensitive rats within 7 days. However, this was animal research, so human studies are needed to confirm the drug works the same way in people. Talk to your doctor about whether it might help your specific situation.
How does dapagliflozin work to lower blood pressure in salt sensitivity?
The drug prevents kidney cells from releasing inflammatory chemicals when exposed to excess protein in urine. This stops a chain reaction that leads to blood pressure increases. Interestingly, it works without reducing overall kidney inflammation, suggesting a different mechanism than previously thought.
Is salt-sensitive hypertension the same as regular high blood pressure?
No. Salt-sensitive hypertension occurs when eating salty foods causes significant blood pressure spikes. Regular high blood pressure may not respond as dramatically to salt changes. About 50% of people with high blood pressure are salt-sensitive, making this research relevant to millions of people.
How quickly does dapagliflozin work for blood pressure?
In rats, benefits appeared within 7 days. In humans, blood pressure medications typically take 2-4 weeks to show full effects as the body adjusts. Long-term benefits beyond a few weeks haven’t been studied yet in this research.
Will this drug work for everyone with high blood pressure?
This research specifically studied salt-sensitive hypertension, so the drug may work best for people whose blood pressure spikes with salt intake. People with other types of high blood pressure may see different results. Individual responses vary, so your doctor should monitor your specific response.
Want to Apply This Research?
- Track daily sodium intake (in milligrams) alongside blood pressure readings at the same time each day. Record readings before and 2 hours after eating salty meals to identify personal salt sensitivity patterns.
- Users taking or considering dapagliflozin should log their salt intake and blood pressure daily using the app’s built-in tracker, then share trends with their doctor at appointments to assess whether the medication is working for their specific salt sensitivity.
- Create a 30-day baseline tracking period to establish personal salt sensitivity (how much blood pressure increases per gram of sodium), then continue weekly tracking after starting medication to measure improvement. Set alerts for high sodium days to help users correlate intake with blood pressure spikes.
This research was conducted in animals (rats) and has not yet been tested in humans. While dapagliflozin is an FDA-approved medication for diabetes, its use for salt-sensitive hypertension is not yet established in humans and would require a doctor’s prescription and supervision. Do not start, stop, or change any blood pressure medication without consulting your healthcare provider. This article is for educational purposes and should not replace professional medical advice. Individual responses to medications vary, and your doctor should monitor your blood pressure and kidney function if considering this treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.